{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T02:48:59Z","timestamp":1791600539855,"version":"4.3.4"},"reference-count":40,"publisher":"MDPI AG","issue":"19","license":[{"start":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T00:00:00Z","timestamp":1791417600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T00:00:00Z","timestamp":1791417600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Clin. Med.","JCM"],"abstract":"<jats:p>Clinical remission, defined as sustained multidomain disease stability encompassing symptom control, freedom from exacerbations and from maintenance oral corticosteroid use, and stable or improved lung function, has emerged as a major therapeutic goal in severe asthma, largely driven by the success of biologic therapies. Consequently, remission is often regarded as an outcome primarily achievable through biologic treatment, whereas the potential contribution of optimized inhaled triple therapy has received comparatively less attention. This narrative review examines the evidence supporting biologic-free clinical remission across difficult-to-treat and severe asthma populations and explores the mechanisms that may contribute to sustained multidomain disease stability during optimized inhaled triple therapy. Importantly, we distinguish remission achieved after correction of previously unrecognized modifiable factors\u2014which may reflect successful management of difficult-to-treat asthma\u2014from on-treatment remission occurring in patients in whom severe asthma had already been established after appropriate treatment optimization. We review contemporary remission definitions, the biological rationale for remission achieved during optimized inhaled therapy, and evidence from historical cohorts, national registries, randomized clinical trials, post hoc analyses, and prospective real-world studies. Collectively, these data indicate that optimized inhaled triple therapy can be associated with clinically meaningful multidomain disease-stability states and, when established remission criteria are fulfilled, clinical remission, although the strength of evidence specifically in patients fulfilling current severe-asthma criteria remains more limited. Particular emphasis is placed on the contribution of small-airway dysfunction, the evolution of the quiet asthma concept as a proposed small-airway remission phenotype, and the potential roles of pharmacological synergy, improved peripheral drug deposition, and restoration of distal airway homeostasis. We also discuss the durability of remission, the need for continued multidomain follow-up, and the clinical and health-economic implications of achieving remission without biologic therapy. Current evidence suggests that optimized inhaled triple therapy should be considered not only a key component of severe asthma management but also a potential remission-oriented strategy in appropriately selected patients, including those who may achieve remission without subsequent biologic escalation. Future research should identify the phenotypes most likely to achieve biologic-free remission, clarify the underlying mechanisms, and prospectively validate remission-oriented inhaled treatment strategies.<\/jats:p>","DOI":"10.3390\/jcm15197757","type":"journal-article","created":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T01:40:17Z","timestamp":1791596417000},"page":"7757","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["From Quiet Asthma to Clinical Remission: Can Optimized Maximal Inhaled Therapy Achieve Biologic-Free Remission in Difficult-to-Treat and Severe Asthma?"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9920-780X","authenticated-orcid":false,"given":"Vitaliano Nicola","family":"Quaranta","sequence":"first","affiliation":[{"name":"Department of Translational Biomedicine and Neurosciences, Institute of Respiratory Disease, University of Bari \u201cAldo Moro\u201d, 70124 Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1563-6864","authenticated-orcid":false,"given":"Silvano","family":"Dragonieri","sequence":"additional","affiliation":[{"name":"Department of Translational Biomedicine and Neurosciences, Institute of Respiratory Disease, University of Bari \u201cAldo Moro\u201d, 70124 Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8265-7959","authenticated-orcid":false,"given":"Gianmarco","family":"Manzetti","sequence":"additional","affiliation":[{"name":"Unit of Respiratory Medicine, Department of Experimental Medicine, University of Rome \u201cTor Vergata\u201d, 00133 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-8508-7728","authenticated-orcid":false,"given":"Alessandra","family":"Tomasello","sequence":"additional","affiliation":[{"name":"Division of Respiratory Medicine, PROMISE Department, Paolo Giaccone University Hospital, University of Palermo, 90127 Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8609-0814","authenticated-orcid":false,"given":"Alida","family":"Benfante","sequence":"additional","affiliation":[{"name":"Division of Respiratory Medicine, PROMISE Department, Paolo Giaccone University Hospital, University of Palermo, 90127 Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6400-6573","authenticated-orcid":false,"given":"Nicola","family":"Scichilone","sequence":"additional","affiliation":[{"name":"Division of Respiratory Medicine, PROMISE Department, Paolo Giaccone University Hospital, University of Palermo, 90127 Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7801-5040","authenticated-orcid":false,"given":"Paola","family":"Rogliani","sequence":"additional","affiliation":[{"name":"Unit of Respiratory Medicine, Department of Experimental Medicine, University of Rome \u201cTor Vergata\u201d, 00133 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanna Elisiana","family":"Carpagnano","sequence":"additional","affiliation":[{"name":"Department of Translational Biomedicine and Neurosciences, Institute of Respiratory Disease, University of Bari \u201cAldo Moro\u201d, 70124 Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,10,8]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.jaci.2019.12.006","article-title":"An expert consensus framework for asthma remission as a treatment goal","volume":"145","author":"Bafadhel","year":"2020","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"3629","DOI":"10.1016\/j.jaip.2023.07.041","article-title":"Severe Asthma Network Italy Definition of Clinical Remission in Severe Asthma: A Delphi Consensus","volume":"11","author":"Canonica","year":"2023","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.pccm.2025.05.001","article-title":"Achieving remission in severe asthma","volume":"3","author":"Thawanaphong","year":"2025","journal-title":"Chin. Med. J. Pulm. Crit. Care Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1164\/rccm.202405-0894ED","article-title":"Remission in the World of Severe Asthma","volume":"210","author":"Pavord","year":"2024","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"240181","DOI":"10.1183\/16000617.0181-2024","article-title":"Pro: Clinical remission in asthma\u2014Implications for asthma management","volume":"34","author":"Principe","year":"2025","journal-title":"Eur. Respir. Rev."},{"key":"ref_6","unstructured":"Global Initiative for Asthma (GINA) (2026). Global Strategy for Asthma Management and Prevention, Global Initiative for Asthma. Available online: https:\/\/ginasthma.org\/2026-gina-strategy-report\/."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1183\/09031936.00121705","article-title":"RHINE Study Group. Remission of asthma: A prospective longitudinal study from northern Europe (RHINE study)","volume":"30","author":"Holm","year":"2007","journal-title":"Eur. Respir. J."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1016\/j.jaip.2020.11.013","article-title":"Remission and Changes in Severity Over 30 Years in an Adult Asthma Cohort","volume":"9","author":"Tupper","year":"2021","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"101016","DOI":"10.1016\/j.waojou.2024.101016","article-title":"SANI (Severe Asthma Network in Italy) study group. Biologics as well as inhaled anti-asthmatic therapy achieve clinical remission: Evidence from the Severe Asthma Network in Italy (SANI)","volume":"18","author":"Canonica","year":"2024","journal-title":"World Allergy Organ J."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2024-7-2","DOI":"10.7573\/dic.2024-7-2","article-title":"Clinical remission and control in severe asthma: Agreements and disagreements","volume":"13","author":"Bosi","year":"2024","journal-title":"Drugs Context"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"103050","DOI":"10.1016\/j.eclinm.2024.103050","article-title":"Roads to remission: Evolving treatment concepts in type 2 inflammatory diseases","volume":"80","author":"Lommatzsch","year":"2025","journal-title":"EClinicalMedicine"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s41073-019-0064-8","article-title":"SANRA-a scale for the quality assessment of narrative review articles","volume":"4","author":"Baethge","year":"2019","journal-title":"Res. Integr. Peer Rev."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S2213-2600(14)70103-1","article-title":"Unlocking the quiet zone: The small airway asthma phenotype","volume":"2","author":"Lipworth","year":"2014","journal-title":"Lancet Respir. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"17","DOI":"10.23736\/S0026-4806.21.07266-9","article-title":"Synergy across the drugs approved for the treatment of asthma","volume":"113","author":"Rogliani","year":"2022","journal-title":"Minerva Med."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Carpagnano, G.E., Portacci, A., Dragonieri, S., Montagnolo, F., Iorillo, I., Lulaj, E., Maselli, L., Buonamico, E., and Quaranta, V.N. (2024). Managing Small Airway Disease in Patients with Severe Asthma: Transitioning from the \u201cSilent Zone\u201d to Achieving \u201cQuiet Asthma\u201d. J. Clin. Med., 13.","DOI":"10.3390\/jcm13082320"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Quaranta, V.N., Montagnolo, F., Portacci, A., Dragonieri, S., Granito, M., Rociola, G., Ferrulli, S., Maselli, L., and Carpagnano, G.E. (2025). Steady Quiet Asthma Without Biologics: One-Year Outcomes of Single-Inhaler Triple Therapy for Severe Asthma with Small Airway Dysfunction. J. Clin. Med., 14.","DOI":"10.3390\/jcm14155602"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2004233","DOI":"10.1183\/13993003.04233-2020","article-title":"Triple therapy in uncontrolled asthma: A network meta-analysis of phase III studies","volume":"58","author":"Rogliani","year":"2021","journal-title":"Eur. Respir. J."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1080\/17476348.2019.1657408","article-title":"A potential role of triple therapy for asthma patients","volume":"13","author":"Cazzola","year":"2019","journal-title":"Expert Rev. Respir. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"105801","DOI":"10.1016\/j.phrs.2021.105801","article-title":"Indacaterol, glycopyrronium, and mometasone: Pharmacological interaction and anti-inflammatory profile in hyperresponsive airways","volume":"172","author":"Rogliani","year":"2021","journal-title":"Pharmacol. Res."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1080\/17425247.2025.2527700","article-title":"Triple extrafine fixed-dose combination in asthma: From randomized controlled trials to real-world evidence","volume":"22","author":"Rogliani","year":"2025","journal-title":"Expert Opin. Drug Deliv."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2102583","DOI":"10.1183\/13993003.02583-2021","article-title":"Asthma remission: What is it and how can it be achieved?","volume":"60","author":"Thomas","year":"2022","journal-title":"Eur. Respir. J."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/02770903.2026.2706355","article-title":"Beyond biologics: Background inhaled therapy shapes remission in severe asthma","volume":"63","author":"Quaranta","year":"2026","journal-title":"J. Asthma"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Ediger, D., Aktepe Sezgin, E.N., T\u00fcl\u00fcmen \u00d6zt\u00fcrk, R., and \u00c7oban, B. (2026). Clinical Remission and Its Determinants in Adult Severe Asthma Patients Receiving Biologic Therapy: A Retrospective Analysis. J. Clin. Med., 15.","DOI":"10.3390\/jcm15020442"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Hozawa, S., Ito, R., Crawford, J., Hibi, R., Moore, A., and Noorduyn, S.G. (2026). Is Clinical Remission, an Ambitious Treatment Goal, Achievable in Patients with Moderate-to-Severe Asthma on Inhaled Therapies: How Ambitious Should We Be?. J. Clin. Med., 15.","DOI":"10.3390\/jcm15041497"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1007\/s12325-025-03442-x","article-title":"Evaluating Asthma Clinical Remission with Inhaled Therapy: Post Hoc Analyses of CAPTAIN","volume":"43","author":"Oppenheimer","year":"2026","journal-title":"Adv. Ther."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"582286","DOI":"10.2147\/JAA.S582286","article-title":"TriMaximize Core team; TriMaximize Core team Real-World Effectiveness and Safety of Single Inhaler Triple Therapy with Beclometasone\/ Formoterol\/ Glycopyrronium in Moderate to Severe Asthma: TriMaximize Study","volume":"19","author":"Gessner","year":"2026","journal-title":"J. Asthma Allergy"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"00054","DOI":"10.1183\/23120541.00054-2026","article-title":"Achieving clinical remission in moderate-to-severe asthma using inhaled triple therapy","volume":"12","author":"Canonica","year":"2026","journal-title":"ERJ Open Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"3185","DOI":"10.1111\/all.70264","article-title":"Small Airways Dysfunction and Remission in Adults with Asthma: A Longitudinal Exploratory Analysis of the AssessmenT of smalL Airways involvemeNT in aSthma (ATLANTIS) Study","volume":"81","author":"Kumar","year":"2026","journal-title":"Allergy"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Noorduyn, S.G., Oppenheimer, J.J., Moore, A.C., Nagase, H., Crawford, J., Poddar, A., Boon, V., Brown, N., Slade, D., and Garcia, G. (2026). Clinical Remission with FF\/UMEC\/VI Versus ICS\/LABA in Uncontrolled Asthma: The PERFORM Pragmatic Randomized Controlled Trial. Adv. Ther., Epub ahead of print.","DOI":"10.1007\/s12325-026-03721-1"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"376","DOI":"10.4168\/aair.2014.6.5.376","article-title":"Small airways dysfunction in asthma: Evaluation and management to improve asthma control","volume":"6","author":"Usmani","year":"2014","journal-title":"Allergy Asthma Immunol. Res."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"552261","DOI":"10.2147\/JIR.S552261","article-title":"Long-Acting Muscarinic Antagonists for the Treatment of Difficult-to-Treat and Severe Asthma: A Narrative Review Focusing on Inflammation from Bench to Bedside","volume":"19","author":"Calzetta","year":"2026","journal-title":"J. Inflamm. Res."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"109030","DOI":"10.1016\/j.rmed.2026.109030","article-title":"Exhaled acetylcholine in breath condensate as a non-invasive biomarker of asthma control: Insights from patients treated with extrafine single-inhaler triple therapy","volume":"261","author":"Quaranta","year":"2026","journal-title":"Respir. Med."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Quaranta, V.N., Portacci, A., Maselli, L., Tornesello, M., Granito, M., Rociola, G., Dragonieri, S., and Carpagnano, G.E. (2025). FeNO 350 mL\/s: Unlocking the Small Airways to Achieve Clinical Remission in Severe Asthma-A Pilot Study. Adv. Respir. Med., 93.","DOI":"10.3390\/arm93050037"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1111\/all.15566","article-title":"Biomarkers of asthma relapse and lung function decline in adults with spontaneous asthma remission: A population-based cohort study","volume":"78","author":"Tan","year":"2023","journal-title":"Allergy"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40733-016-0029-3","article-title":"Asthma costs and social impact","volume":"3","author":"Nunes","year":"2017","journal-title":"Asthma Res. Pract."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1186\/s12931-018-0855-3","article-title":"Health care resource utilization and cost for asthma patients regularly treated with oral corticosteroids\u2014A Swedish observational cohort study (PACEHR)","volume":"19","author":"Janson","year":"2018","journal-title":"Respir. Res."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1164\/rccm.201904-0903SO","article-title":"Systematic Literature Review of Systemic Corticosteroid Use for Asthma Management","volume":"201","author":"Bleecker","year":"2020","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/all.13556","article-title":"Healthcare resource utilization and costs associated with incremental systemic corticosteroid exposure in asthma","volume":"74","author":"Voorham","year":"2019","journal-title":"Allergy"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"100718","DOI":"10.1016\/j.jacig.2026.100718","article-title":"The AIM4 Next Step study: Comparing inhaled corticosteroid dose escalation to dupilumab in patients with uncontrolled asthma and type 2 inflammation","volume":"5","author":"Busse","year":"2026","journal-title":"J. Allergy Clin. Immunol. Glob."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"aamag162.452","DOI":"10.1093\/ajrccm\/aamag162.452","article-title":"Benralizumab add-on therapy in patients with eosinophilic asthma uncontrolled on medium-dose inhaled corticosteroid-long-acting \u03b22-agonist (ICS-LABA) versus conventional escalation to high-dose ICS-LABA: Design of the randomized BRISOTE study [abstract]","volume":"212","author":"Bourdin","year":"2026","journal-title":"Am. J. Respir. Crit. Care Med."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/19\/7757\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T01:55:50Z","timestamp":1791597350000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/19\/7757"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,8]]},"references-count":40,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["jcm15197757"],"URL":"https:\/\/doi.org\/10.3390\/jcm15197757","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,8]]}}}